The Bone Marrow Stem Cell Transplant Program is at the forefront of medicine as it regards the treatment of hematological malignancies and cancers, and performs allogeneic, autologous, and cord transplants. For patients undergoing allogeneic transplant, we offer some innovative and effective approaches such as haplomismatched, non-myeloblative (mini transplants), and donor leukocyte infusion (DLI). After a decade of successfully treating a variety of diseases, the program has gone from being perceived as experimental, to regarded as the standard option for the treatment of certain types of diseases. The program will continue to find new ways to improve the quality of life for cancer patients. Every Faculty Practice Associate in the program is also a staff member of the Mount Sinai Hospital and the Icahn School of Medicine.
Erik Lium, PhD, Named Vice President of Mount Sinai Innovation Partners
March 31, 2014 - Dr. Lium previously held the post of Assistant Vice Chancellor for Innovation, Technology and Alliances at the University of California, San Francisco.
The Bone Marrow Transplant FPA is open from 9 A.M. to 5 P.M., Monday through Friday.